4.2 Article

Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience

期刊

PITUITARY
卷 15, 期 2, 页码 215-221

出版社

SPRINGER
DOI: 10.1007/s11102-011-0313-4

关键词

Acromegaly; OGTT; Growth hormone; IGF-I

资金

  1. MIUR [2002067251-001, 2007RFFFFN_005]
  2. University of Genova
  3. Italian Minister of Instruction, University and Research [2008LFK7J5_004]

向作者/读者索取更多资源

The objective of this study is to assess the secretory pattern of GH after Oral Glucose Tolerance Test (OGTT) or day-curve (DC), in relation with IGF-I and to evaluate the influence of therapy on OGTT. A retrospective analysis in 279 OGTTs performed in 93 acromegalic patients in our unit from January 1988 to December 2005, in 77 patients also DC data were retrived. GH concentration was evaluated by 3 different systems (RIA, IRMA and chemiluminescence assays), and IGF-I by two RIAs. About 12% of OGTT samples were discordant with the baseline, while discordance between nadir and 120th minute was much lower (5%), with all discordant values, except one, near the cut-off lines. Correlation between DC and OGTT data was around 0.99 among all values, discordance rate between nadir and minimum DC was much lower than that with mean DC. In almost 80% of cases there was a complete concordance between OGTT and DC results, and in about 30% IGF-I was discordant with GH. Correlation analysis between IGF-I and GH was highest with DC data and lowest with OGTT baseline (T0). Considering different treatments discrepancy rates between GH and IGF-I were comparable. The best GH parameter is the minimum GH DC, although in the clinical practice the evaluation of OGTT GH in association with IGF-I is the most practical approach. In this case, the basal and T120 GH values can replace multiple sampling. Different treatment modalities do not influence the discordance rate between GH and IGF-I.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Health Care Sciences & Services

Octreotide-Resistant Acromegaly: Challenges and Solutions

Giuliana Corica, Marco Ceraudo, Claudia Campana, Federica Nista, Francesco Cocchiara, Mara Boschetti, Gianluigi Zona, Diego Criminelli, Diego Ferone, Federico Gatto

THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2020)

Review Pharmacology & Pharmacy

Emerging drugs for the treatment of acromegaly

Claudia Campana, Giuliana Corica, Federica Nista, Francesco Cocchiara, Giulia Graziani, Keyvan Khorrami, Marta Franco, Mara Boschetti, Diego Ferone, Federico Gatto

EXPERT OPINION ON EMERGING DRUGS (2020)

Article Endocrinology & Metabolism

Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment

Claudia Campana, Francesco Cocchiara, Giuliana Corica, Federica Nista, Marica Arvigo, Jessica Amaru, Diego Criminelli Rossi, Gianluigi Zona, Diego Ferone, Federico Gatto

Summary: Discordance between GH and IGF-1 levels in acromegaly patients is influenced by GH cutoff values. The use of GH(m) can mitigate the impact of GH cutoffs and improve predictive accuracy. Fasting GH levels (both GH(f) and GH(m)) are poor predictors of IGF-1 normalization in this cohort.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

Article Endocrinology & Metabolism

Present and future of immunotherapy in Neuroendocrine Tumors

Manuela Albertelli, Andrea Dotto, Federica Nista, Alessandro Veresani, Luca Patti, Stefano Gay, Stefania Sciallero, Mara Boschetti, Diego Ferone

Summary: Despite the lack of robust evidence supporting the role of immunotherapy in the treatment of neuroendocrine neoplasms, future research should focus on strategies to make NETs more susceptible to response to immune checkpoint inhibitors (ICIs). The combination of conventional therapy, target therapy, and immunotherapy deserves attention, along with the exploration of biomarkers for patient selection in this type of treatment.

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2021)

Letter Endocrinology & Metabolism

Acromegaly Management in a Tertiary Referral Center After 1 Year of the Coronavirus 2019 Pandemic: A Double Challenge

Federico Gatto, Keyvan Khorrami, Federica Nista, Giuliana Corica, Diego Ferone

ENDOCRINE PRACTICE (2021)

Review Endocrinology & Metabolism

The effect of sodium restriction on iodine prophylaxis: a review

F. Nista, M. Bagnasco, F. Gatto, M. Albertelli, L. Vera, M. Boschetti, N. Musso, D. Ferone

Summary: Sodium is essential for life, but excessive dietary intake can be detrimental to the cardiovascular system. Sodium restriction plays a crucial role in cardiovascular prevention. However, iodine deficiency remains a concern in both developing and industrialized countries, and it may affect dietary sodium reduction programs. The source of dietary iodine varies among countries, and there have been significant changes in iodine status in many countries in recent years. More research is needed to better understand the possible effects of sodium restriction on iodine status.

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2022)

Article Oncology

Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise

Mirco Bartolomei, Alfredo Berruti, Massimo Falconi, Nicola Fazio, Diego Ferone, Secondo Lastoria, Giovanni Pappagallo, Ettore Seregni, Annibale Versari

Summary: International guidelines on the management of neuroendocrine neoplasms provide a solid foundation, but expert opinion remains important due to limited clinical evidence and the diverse nature of NENs. A group of experts formulated 14 statements addressing controversial issues in diagnosis and treatment, covering a wide range of topics from initial prognosis to personalized therapeutic approaches.

CANCERS (2022)

Article Nutrition & Dietetics

Prevalence of Lactose Intolerance in Patients with Hashimoto Thyroiditis and Impact on LT4 Replacement Dose

Elisa Marabotto, Diego Ferone, Afscin Djahandideh Sheijani, Lara Vera, Sebastiano Ziola, Edoardo Savarino, Giorgia Bodini, Manuele Furnari, Patrizia Zentilin, Vincenzo Savarino, Massimo Giusti, Fabiola Andrea Navarro Rojas, Marcello Bagnasco, Manuela Albertelli, Edoardo G. Giannini

Summary: This study evaluated the prevalence of lactose intolerance (LI) in women with Hashimoto's thyroiditis (HT) and its impact on LT4 replacement dose. The results showed that LI does not seem to be a major cause of LT4 malabsorption and does not affect the required LT4 dose in HT patients, when other gastrointestinal disorders are absent.

NUTRIENTS (2022)

Article Endocrinology & Metabolism

Appropriate management of growth hormone deficiency during the age of transition: an Italian Delphi consensus statement

S. Cannavo, M. Cappa, D. Ferone, A. M. Isidori, S. Loche, M. Salerno, M. Maghnie

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2023)

Editorial Material Endocrinology & Metabolism

Routine Evaluation of Somatostatin Receptor Type 2 in Patients With Acromegaly: Do We Still Need More Evidence?

Federico Gatto, Luiz Eduardo Wildemberg, Diego Ferone, Monica R. Gadelha

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Article Medicine, General & Internal

Trabecular Bone Score as a Reliable Measure of Lumbar Spine Bone Microarchitecture in Acromegalic Patients

Elena Nazzari, Andrea Casabella, Sabrina Paolino, Claudia Campana, Giuliana Corica, Federica Nista, Angelo Milioto, Alberto Tagliafico, Manuela Albertelli, Mara Boschetti, Marcello Bagnasco, Maurizio Cutolo, Diego Ferone, Federico Gatto

Summary: This study found that acromegalic patients have significantly lower trabecular bone scores (TBS) compared to healthy controls, indicating impaired lumbar spine microarchitecture. Uncontrolled disease and hypogonadism contribute to the deterioration of TBS in acromegaly.

JOURNAL OF CLINICAL MEDICINE (2022)

Article Endocrinology & Metabolism

Dissecting the In Vitro Efficacy of Octreotide and Cabergoline in GH- and GH/PRL-Secreting Pituitary Tumors

Federico Gatto, Richard A. Feelders, Peter M. van Koetsveld, Fadime Dogan, Sebastian J. C. M. M. Neggers, Aart-Jan van der Lelij, Jessica Amaru, Diego Ferone, Leo J. Hofland

Summary: Cabergoline (CAB) is an off-label medical therapy for acromegaly, but it is overshadowed by first-generation somatostatin receptor ligands like octreotide (OCT). In this study, OCT was found to be slightly more effective than CAB in inhibiting growth hormone (GH) secretion in vitro. Additionally, the response to CAB treatment was shown to be better in GH/prolactin (PRL) co-secreting tumors.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2023)

Article Endocrinology & Metabolism

Modulatory activity of testosterone on growth pattern and IGF-1 levels in vanishing testis syndrome: a case report during 15 years of follow-up

Marta Franco, Keyvan Khorrami Chokami, Manuela Albertelli, Claudia Teti, Francesco Cocchiara, Federico Gatto, Carlo Trombetta, Diego Ferone, Mara Boschetti

Summary: This article reports a case study of a young man affected by vanishing testis syndrome (VTS) who had been followed up in our center for over 15 years. The patient received different testosterone formulations that adjusted his IGF-1 levels and growth velocity, mimicking the pubertal spurt and achieving a final height in line with his genetic target. Accurate monitoring of VTS patients and a precise reproduction of testosterone secretion during the pubertal spurt can ensure normal growth and development, leading to a high quality of life in adulthood.

BMC ENDOCRINE DISORDERS (2023)

Article Endocrinology & Metabolism

A comparative cross-sectional study on sleep quality in patients with a history of differentiated thyroid carcinoma and its correlation with quality of life

Marsida Teliti, Eleonora Monti, Martina Comina, Lucia Conte, Lara Vera, Stefano Gay, Giorgia Saccomani, Diego Ferone, Massimo Giusti

Summary: The study found that abnormal sleep components and insomnia were similar in patients with differentiated thyroid carcinoma (DTC) and those undergoing surgery for benign pathology. The ThyPRO questionnaire closely reflected sleep disturbances in all subjects, emphasizing the importance of recognizing and treating sleep disturbances to improve quality of life.

ENDOCRINE (2021)

暂无数据